Unknown

Dataset Information

0

Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.


ABSTRACT: To conduct a phase II trial in chemoresistant hairy cell leukemia (HCL) with BL22, a recombinant anti-CD22 immunotoxin which showed phase I activity in HCL.Eligible patients had relapsed/refractory HCL and needed treatment based on blood counts. Patients were stratified into three groups: response to cladribine less than 1 year, those with a response lasting 1 to 4 years, or no response and uncontrolled infection. Patients received BL22 40 microg/kg every other day for three doses on cycle 1. Those achieving hematologic remission (HR), defined as neutrophils > or = 1,500/mm(3), hemoglobin > or = 11 g/dL, and platelets > or = 100,000/mm(3), were observed. Patients without HR were re-treated at 30 microg/kg every other day for three doses every 4 weeks beginning at least 8 weeks after cycle 1.Thirty-six patients were enrolled including 26, nine, and one in groups 1 to 3. The response after one cycle (CR, 25%; PR, 25%) improved when 56% were re-treated (CR, 47%; PR, 25%). CR rate was similar in groups 1 and 2 (P = .7). Twenty-two with baseline spleen height lower than 200 mm had higher CR (64% v 21%; P = .019) and OR rates (95% v 36%; P = .0002) compared to 14 with spleens either absent or higher than 200 mm. The only serious toxicity was reversible grade 3 hemolytic uremic syndrome, not requiring plasmapheresis, in two patients (6%). High neutralizing antibodies were observed in four patients (11%) and prevented re-treatment.BL22 activity in HCL is confirmed. Best responses to BL22 after cladribine failure are achieved before the patients develop massive splenomegaly or undergo splenectomy.

SUBMITTER: Kreitman RJ 

PROVIDER: S-EPMC2702232 | biostudies-literature | 2009 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.

Kreitman Robert J RJ   Stetler-Stevenson Maryalice M   Margulies Inger I   Noel Pierre P   Fitzgerald David J P DJ   Wilson Wyndham H WH   Pastan Ira I  

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090504 18


<h4>Purpose</h4>To conduct a phase II trial in chemoresistant hairy cell leukemia (HCL) with BL22, a recombinant anti-CD22 immunotoxin which showed phase I activity in HCL.<h4>Patients and methods</h4>Eligible patients had relapsed/refractory HCL and needed treatment based on blood counts. Patients were stratified into three groups: response to cladribine less than 1 year, those with a response lasting 1 to 4 years, or no response and uncontrolled infection. Patients received BL22 40 microg/kg e  ...[more]

Similar Datasets

| S-EPMC3383181 | biostudies-literature
| S-EPMC5344129 | biostudies-literature
| S-EPMC2840067 | biostudies-literature
| S-EPMC7213585 | biostudies-literature
| S-EPMC9028144 | biostudies-literature
| S-EPMC4081440 | biostudies-literature
| S-EPMC5396841 | biostudies-literature
| S-EPMC9153043 | biostudies-literature
| S-EPMC5514929 | biostudies-literature
| S-EPMC8225920 | biostudies-literature